GlassScriptPhysician profile
Syed A Rizvi
NPI 1770511446
$160,090.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $6,498 · 2021: $2,340 · 2022: $13K · 2023: $13K · 2024: $5,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,338 · Honoraria: $6,050 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Travel and Lodging: $911 · Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,338.00 |
| Honoraria | $6,050.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Travel and Lodging | $911.36 |
| Food and Beverage | $478.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42,531.23 | 2019-2022 | |
| Genzyme Corporation | $36,429.63 | 2019 | |
| Biogen, INC. | $27,079.83 | 2019 | |
| Emd Serono, INC. | $24,765.38 | 2019-2022 | |
| Horizon Therapeutics Plc | $8,807.66 | 2022-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $4,429.00 | 2019 | |
| Amgen INC. | $3,557.54 | 2024 | Uplizna |
| F. Hoffmann-La Roche Ag | $3,549.00 | 2023 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $2,686.09 | 2019-2024 | |
| Tg Therapeutics, INC. | $2,588.00 | 2023-2024 | |
| Celgene Corporation | $1,440.00 | 2021 | |
| Cycle Pharmaceuticals INC | $1,300.00 | 2023 | |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.